Based on our previously published TAG vaccine design and the TAG vaccine clinical results to date (which demonstrate safety and evidence of efficacy — stabilizing disease plus one confirmed complete response; data submitted elsewhere), we have moved forward with a fundamentally new autologous tumor cell vaccine design incorporating a key technical enhancement through our proprietary bifunctional shRNA technology. The resulting FANG vaccine expresses both recombinant human GM-CSF protein and a furin bifunctional shRNA which blocks the expression of furin protein, and then in turn, significantly reduces the expression of both TGFß1 and TGFß2 in all primary human tumors tested to date…
Tag: <span>autologous tumor vaccine production</span>
Preliminary studies with a variety of cell-based vaccines suggest target accessibility (potential immunogenicity) to immune-directed approaches in a variety of solid tumors. However, four primary factors limit the generation of effective immune-mediated anticancer activity in therapeutic applications: 1) identifying and/or targeting cancer-associated immunogen(s) (target) in an individual patient; 2) insufficient or inhibited level of antigen-presenting cell (dendritic cell, macrophage) priming and/or presentation; 3) suboptimal T cell activation (potency) and proliferation; and 4) cancer-induced inhibition of the anticancer immune response in both afferent and efferent limbs…